Discovery and replication of SNP-SNP interactions for quantitative lipid traits in over 60,000 individuals by Holzinger, Emily R. et al.
Holzinger et al. BioData Mining  (2017) 10:25 
DOI 10.1186/s13040-017-0145-5RESEARCH Open AccessDiscovery and replication of SNP-SNP
interactions for quantitative lipid traits in
over 60,000 individuals
Emily R. Holzinger1*, Shefali S. Verma2, Carrie B. Moore3, Molly Hall2, Rishika De4, Diane Gilbert-Diamond5,
Matthew B. Lanktree6, Nathan Pankratz7, Antoinette Amuzu8, Amber Burt9, Caroline Dale8, Scott Dudek2,
Clement E. Furlong9, Tom R. Gaunt10, Daniel Seung Kim9, Helene Riess11, Suthesh Sivapalaratnam12,
Vinicius Tragante13,14, Erik P.A. van Iperen15,16, Ariel Brautbar17, David S. Carrell18, David R. Crosslin9, Gail P. Jarvik9,
Helena Kuivaniemi19, Iftikhar J. Kullo20, Eric B. Larson18, Laura J. Rasmussen-Torvik21, Gerard Tromp19,
Jens Baumert11, Karen J. Cruickshanks22, Martin Farrall23, Aroon D. Hingorani24, G. K. Hovingh12, Marcus E. Kleber25,
Barbara E. Klein22, Ronald Klein22, Wolfgang Koenig26, Leslie A. Lange27, Winfried Mӓrz25,28, Kari E. North29,
N. Charlotte Onland-Moret30, Alex P. Reiner31, Philippa J. Talmud32, Yvonne T. van der Schouw30,
James G. Wilson33, Mika Kivimaki24, Meena Kumari24,34, Jason H. Moore35, Fotios Drenos32,36,
Folkert W. Asselbergs13,15,36, Brendan J. Keating37,38*† and Marylyn D. Ritchie39*†* Correspondence:
emily.holzinger@nih.gov;
bkeating@mail.med.upenn.edu;
mdritchie@geisinger.edu
†Equal contributors
1Computational and Statistical
Genomics Branch, National Human
Genome Research Institute, National
Institute for General Medical
Sciences, National Institutes of
Health, Baltimore, MD, USA
37Division of Genetics, The
Children’s Hospital of Philadelphia,
Philadelphia, PA, USA
39Biomedical and Translational
Informatics, Geisinger Clinic,
Danville, PA, USA
Full list of author information is
available at the end of the articleAbstract
Background: The genetic etiology of human lipid quantitative traits is not fully
elucidated, and interactions between variants may play a role. We performed a
gene-centric interaction study for four different lipid traits: low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol
(TC), and triglycerides (TG).
Results: Our analysis consisted of a discovery phase using a merged dataset of five
different cohorts (n = 12,853 to n = 16,849 depending on lipid phenotype) and a
replication phase with ten independent cohorts totaling up to 36,938 additional
samples. Filters are often applied before interaction testing to correct for the burden
of testing all pairwise interactions. We used two different filters: 1. A filter that tested
only single nucleotide polymorphisms (SNPs) with a main effect of p < 0.001 in a
previous association study. 2. A filter that only tested interactions identified by
Biofilter 2.0. Pairwise models that reached an interaction significance level of
p < 0.001 in the discovery dataset were tested for replication. We identified
thirteen SNP-SNP models that were significant in more than one replication
cohort after accounting for multiple testing.
Conclusions: These results may reveal novel insights into the genetic etiology of
lipid levels. Furthermore, we developed a pipeline to perform a computationally
efficient interaction analysis with multi-cohort replication.
Keywords: Genetics, Lipids, Interactions, Computational genetics, Genetic
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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For this study, we perform several analyses to identify and validate genetic interactions
associated with circulating lipid levels. Our motivation for studying the contribution of
interactions to lipid levels is three-fold. First, dyslipidemia have a large impact on
human health. Circulating lipid levels, such as high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and
triglycerides (TG), are associated with risk for various common disease traits includ-
ing cardiovascular disease [1]. Cardiovascular disease is the leading cause of death
for individuals in developed countries [2]. Secondly, the estimated genetic compo-
nent for lipid levels is relatively large and highly variable. While age, sex, body mass
index (BMI), diet, exercise and smoking status have been shown to have an effect on
lipid levels, it is estimated that genetic factors contribute between 40 and 60% overall
to variation in lipid levels [3, 4]. A more thorough understanding of the genetics
underlying individual variation in lipid levels will result in greater insight into the
biological processes underpinning dyslipidemia, and may inform more effective ther-
apies to ultimately lower risk for cardiovascular disease. Lastly, a large portion of the
estimated genetic component has not been identified by main effects alone. For the
past decade or so, large efforts have been undertaken to tease apart the genetic eti-
ology of common, complex traits, such as circulating lipid level and CVD; however a
large proportion of the estimated heritability of these traits that remains unexplained
[5, 6]. Sources of missing heritability are likely to be caused by rare variants, epigen-
etics, structural variation, gene-gene interactions, gene-environment interactions,
and/or the accuracy of the heritability models [7, 8]. Notably, calculating the total
heritability and measuring the exact contribution of these specific findings to herit-
ability remains a controversial and complex issue [9–12]. However, the consistently
small proportion explained by common variants identified by GWAS across all com-
plex traits suggests that we still have a lot to learn about the genetic architecture of
these traits. This study addresses the contribution of interactions to the genetic
architecture of lipid traits by examining SNP-SNP interactions in four quantitative
lipid traits – HDL-C, LDL-C, TC, and TG.
Here we are trying to identify genetic interactions by searching for statistical interac-
tions. For interpretation purposes, it is important to understand how we define an
interaction. Biologically, we are trying to identify genetic variants that alter the pheno-
type in a manner that is dependent on genotypes at two different loci. For example, an
individual may have variants in two different regions of a metabolic enzyme protein
that cause triglyceride levels to increase even more than the combined additive effects
of the variants. Statistically, we use a likelihood ratio test to assess the significance of
including a multiplicative interaction term along with the two main effect terms in a
linear regression model. While there has been some debate about the relationship be-
tween statistical and biological interactions, there is substantial evidence that this
method is robust to the non-linear or interaction effects we are interested in [13].One
of the main considerations for a genome-wide interaction study (GWIS) is the compu-
tational and statistical burden of exhaustive interaction testing, which inherently results
in a massive increase in the number of tests (e.g. 1000 SNPs = 499,500 two-way inter-
actions and 166,167,000 three-way interactions, etc.). While our analysis is not a GWIS
per se, as most individuals were genotyped using a cardiovascular gene-centric array
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apply [14]. One approach to address this issue is to filter on main effect significance
(i.e. the p-value from the main effect term in a regression model) using bona fide index
lipid signals derived from existing GWAS. A limitation to the main effect filter ap-
proach is that SNPs involved in true interactions with little or no main effects will likely
be filtered out. Another approach is to select SNP-SNP models based on knowledge-
driven biologically plausible genes/loci, such as selecting SNP pairs in genes shown to
physically interact in previous biological experiments (Biofilter) [15].
For this analysis, we used both of the aforementioned filter methods to test for inter-
actions. After applying these filters, we identified potential SNP-SNP interactions for
each of the lipid traits in a discovery analysis, which consisted of five cohorts merged
into one dataset (n = 12,853 to n = 16,849 depending on lipid phenotype): Atheroscler-
osis Risk In Communities (ARIC); Coronary Artery Risk Development in Young Adults
(CARDIA); Cardiovascular Health Study (CHS); Framingham Heart Study (FHS); and
Multi-Ethnic Study of Atherosclerosis (MESA); from the NHLBI Candidate gene Asso-
ciation Resource (CARe). Models were selected for replication testing based on statis-
tical significance from the discovery set. There were ten replication sets in total with
sample sizes between n = 1568 and n = 7504 totaling 36,938 for the replication dataset.
We identified models with the most evidence for significant associations with the lipid
traits according multiple-testing corrected likelihood ratio test p-value thresholds from
linear regression models. We also assessed the number of cohorts in which the models
replicated. This study highlights an analysis strategy to explore genetic interactions for
complex traits and suggests several replicating interactions for lipid traits.Methods
Discovery: Cohort descriptions
The discovery dataset for each of the traits had n ~ 14,000, with each of the cohorts
having the following contributions: ARIC (n = 11,906), CARDIA (n = 2319), CHS
(n = 4490), FHS (n = 1467), and MESA (n = 5598). Individuals were genotyped using
the gene-centric ITMAT-Broad-CARe (IBC) array [16], which was previously used in a
meta-analysis of 32 studies (66,240 individuals), identifying and replicating many known
and novel lipid signals [17]. All of the individuals in our analysis were self-reported
European ancestry, subsequently verified using principal component analyses by
selecting individuals that clustered with the CEU panel from HapMap, and ≥21 years
of age. HDL-C, LDL-C, TC, and TG levels were measured from baseline or first
measurement blood samples. All lipid measurements were converted to mmol/L.
LDL-C was calculated according to Friedewald’s formula L ~ C – H - kT where C is total
cholesterol, H is HDL, L is LDL, T are triglycerides, and k is 0.45 for mmol/L (or 0.20 if
measured in mg/dl). If TG values were >4.51 mmol/L (>400 mg/dL), then LDL was
treated as a missing value. More details for the five merged discovery cohorts are shown
in Table 1.Discovery: Quality control and statistical analyses
Individuals were genotyped on the ITMAT-Broad-CARe (IBC) array. This array con-
sists of ~50,000 SNPs across ~2100 loci. Selection criteria for SNPs to be included on
Table 1 Details for the five cohorts that were merged to create the discovery dataset and the 10
cohorts used for replication
Study (One
letter label)
Recruitment design Year of
collection
N
totala
Data
Level
Study Ref (PMID)
Discovery
(IBC)
ARIC Community-based 1985–2006 9588 Individual 20400780
CARDIA Community-based 1985–2003 1443 Individual 20400780
CHS Community-based 1988–2005 3952 Individual 20400780
FHS Community-based 1948-present 7556 Individual 20,400,780
MESA Community-based 1999–2009 2298 Individual 20400780
Replication
(IBC)
BOSS/EHLS/BDES Population-based
cohort
1988-present 1568 Summary 21339392, 9801018,
1923372
BWHHS (B) Population-based
cohort
1999–2001 3411 Summary 16045529
CLEAR Case-control 2005 1591 Summary 16474172
EPIC-NL Nested case-control 1993–1997 5194 Summary 19483199
GIRaFH Cohort 1999 1694 Summary 15554949
KORA Population-based
cohort
1984–2005 1849 Summary 16032513, 1603251
LURIC (L) Case-control 1997–2002 2813 Summary 11258203
PROCARDIS (P) Case-control 1998-present 6432 Summary 20032323
Whitehall II (W) Population-based
cohort
1985–1989 4882 Summary 15576467
Rep. (GWAS) eMERGE Consortium 7504 Summary 23743551
Discovery cohorts: Atherosclerosis Risk In Communities (ARIC); Coronary Artery Risk Development in Young Adults
(CARDIA); Cardiovascular Health Study (CHS); Framingham Heart Study (FHS); Multi-Ethnic Study of Atherosclerosis (MESA)
Replication cohorts: BOSS beaver dam offspring study, EHLS epidemiology of hearing loss study, BDES beaver dam eye
study, AIBIII Allied Irish Bank Workers Study III, AMC-PAS Academic Medical Center Amsterdam Premature Atherosclerosis
Study, ASCOT anglo-scandinavian cardiac outcomes trial, BHS bogalusa heart study, BRIGHT, British genetics of hypertension,
BWHHS British women’s heart and health study, CLEAR carotid lesion epidemiology and risk, EPIC-NL European Prospective
Investigation into Cancer and Nutrition in the Netherlands, GIRaFH genetic identification of risk factors in familial
hypercholesterolemia, KORA Kooperative Gesundheitsforschung in der Region Augsburg, LURIC Ludwigshafen Risk
and Cardiovascular Health Study, PROCARDIS precocious coronary artery disease study, WHII Whitehall II study,
GWAS eMERGE
aNumbers varied for each lipid trait. The number shown is the maximum number of non-missing individuals for all traits
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applied after the cohorts were merged into the full discovery dataset. A summary of the
full quality control and analysis pipeline is shown in Fig. 1. All quality control proce-
dures were implemented with the PLINK software package [18] unless otherwise speci-
fied. SNPs with a genotype missing rate > 95% or that were not in Hardy-Weinberg
equilibrium (p < 1.0 x < 10−7) were removed from the analysis. After SNP genotyping
quality control, 44,750 markers remained. Individuals with SNP genotype missing rates
>90% were excluded from the analysis. For cohorts that contained known trios, non-
founders (i.e. offspring) were removed. To address unknown or cryptic relatedness,
identity-by-descent (IBD) estimates were calculated, and one individual from each pair
with pi-hat >0.3 was removed. The TG values were log transformed to improve normal-
ity. Four new datasets were created for each of the quantitative lipid traits: HDL-C
(n = 13,030), LDL-C (n = 12,853), TC (n = 16,849), and TG (n = 13,031).
Additional quality control metrics were applied to the individual lipid datasets for
each of the statistical analyses. For both the main effect filter and Biofilter analyses,
SNPs with missing phenotypes were removed along with variants with minor allele fre-
quency (MAF) < 0.05 or missing genotype rate > 5%. For the main effect filter analysis,
Fig. 1 Flowchart of the quality control and analysis steps for the discovery and replication phases
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LD pruning was done for the Biofilter interaction analyses, as these models are specific-
ally generated using SNPs that are in different genes. This was performed by removing
one SNP from all pairs of SNPs with an r2 > 0.6 using PLINK. SNPs with a main effect
p < 0.001 based on a previous GWAS regression analysis were selected for interaction
testing [17]. We had two specific motivations for selecting this threshold for our study:
1. to allow for interactions that may be present in the absence of large, genome-wide
significant main effects, and 2. to reduce the SNP set to a size that allowed for a man-
ageable exhaustive SNP-SNP interaction analysis. SNP-SNP models were generated by
creating an exhaustive list of all SNP pairs. Importantly, we did not LD prune for the
Biofilter analysis due to the method used to generate SNP-SNP models. Biofilter 2.0 is
a software package that identifies SNP-SNP models based on probable gene-gene inter-
actions identified in various online sources including Gene Ontology GO and KEGG.
The Biofilter method has previously been described in greater detail [15, 19]. Briefly,
SNPs are mapped to genes using a 50 kb upstream or downstream inclusion criterion.
Gene pairs that may be more likely to interact are then identified in various curated
biological knowledge databases. A score is given based on the number of sources that
indicate a possible interaction. For this analysis, models were included if at least five
knowledge sources identified the gene-gene interaction model. The SNPs are then
mapped back to the genes to create the SNP-SNP models for statistical testing.
To test for SNP-SNP interactions, we used an R script that automatically tests the
models according to user input parameters [20]. We tested for significant interactions
using a linear regression framework. We adjusted for age, sex, smoking status, type 2
diabetes status, BMI, medication use (use or no use of lipid lowering drugs), and potential
population substructure (top 10 principal components) by including these as covariate
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covariates to control for any factors outside of genetics that may have an effect on lipid
levels and to remain consistent with the previous GWAS from which the SNPs for the
main effect filter analysis were chosen. In the previous study that used the same lipid mea-
surements for a gene-centric meta-analysis of main effects [17], an additional adjustment
for medication was done by multiplying a constant percentage to account for lipid lower-
ing medication. The two adjustment methods (covariate and multiplication) gave similar
results; therefore, we only included the covariate adjustment results in this manuscript.
We chose to include the top 10 principal components to remain consistent with the previ-
ous GWAS and to control for any residual variation as we were performing these analyses
in a combined cohort that included individuals from various parts of the country. Models
were selected for replication testing with likelihood ratio test p -values <0.001 (comparing
the full and reduced linear regression models (Eqs. 1 and 2)). We adjusted the threshold
using a Bonferroni correction based on the total number of number of models that were
tested for each filtering methods. We estimated these models to be independent due to
the LD-pruning in the main effect filter analysis and the SNPs being in different genes for
the Biofilter analysis (Fig 1).
reduced : y ¼ αþ β1 SNP1ð Þ þ β2 SNP2ð Þ þ β3 ageð Þ þ β4 BMIð Þ þ β5 med:ð Þ
þ β6 T2Dð Þ þ β7 smokingð Þ þ β8 sexð Þ þ β9−18 PC1−PC10ð Þ
ð1Þ
full : y ¼ αþ β1 SNP1ð Þ þ β2 SNP2ð Þ þ β3 ageð Þ þ β4 BMIð Þ þ β5 med:ð Þ
þ β6 T2Dð Þ þ β7 smokingð Þ þ β8 sexð Þ þ β9−18 PC1−PC10ð Þ
þβ19 SNP1SNP2ð Þ
ð2Þ
The full model consisted of the same SNP and covariate terms as the reduced model,
but with an additional multiplicative interaction term for the SNP-SNP model. We gen-
erated “proxy” models by identifying SNPs in high linkage disequilibrium (LD)
(r2 > 0.8) with model SNPs based on the HapMap European CEPH (CEU) population
in 1000 Genomes Project Pilot 1 data (2010 release) using SNAP [21]. We generated a
list of proxy SNP-SNP models using the SNPs in high LD with the original model SNPs
to represent the original model from the discovery set. The purpose of these models
was to capture signals in the replication data that may have been missed due to allele
frequency differences between the discovery and replication cohorts. The original and
proxy models from the discovery analysis were tested in each of the replication cohorts.
Replication: Cohort descriptions
The top original and proxy models from the main effect filter and Biofilter analyses
were tested in ten independent replication cohorts – BOSS/EHLS/BDES, CLEAR,
eMERGE, EPIC, GIRaFH, KORA, LURIC, PROCARDIS, Whitehall II, and BWHHS.
All of the replication cohorts, except the eMERGE datasets, were genotyped using the
IBC array; therefore, many of the proxy models were not tested because many of the
proxy SNPs are not on the IBC array.
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linked to data from patient electronic medical records (EMR) [22]. The eMERGE set
was genotyped with the Illumina660W GWAS platform and further imputed using
1000 Genomes project data, as described here [23]. The replication set consisted of
data from the Marshfield Clinic, Northwestern University, Group Health Cooperative,
Mayo Clinic, and Vanderbilt University. After quality control, the final eMERGE sample
size was n = 7502 for all lipid traits. Details on quality control and phenotype extrac-
tions from the EMR can be found here [24].
The minimum variant and sample call rate threshold for all replication cohorts was
0.95 and 0.90, respectively. A Hardy-Weingberg equilibrium test p-value threshold of at
least p < 1 × 10−6 was applied by each group. In each of the replication cohorts, popu-
lation stratification and relatedness were assessed and adjusted for accordingly. All of
the individuals in the replication cohorts were of European-American descent. The full
details for the QC procedures can be found in the references provided for each replica-
tion cohort in Table 1.Replication: Quality control and statistical analyses
Replication analyses were performed in nine independent cohorts genotyped previously
on the IBC array for a range of phenotypes including lipid levels [17] and the eMERGE
cohort, which contained GWAS genotype data (Fig 1). For each of the ten cohorts, all of
the models from the discovery analysis with LRT p < 0.001 and all of the corresponding
proxy models were tested using the same statistical approach as for the discovery analysis
(Eqs. 1 and 2). The same statistical approach was applied in the replication analysis as for
the discovery analysis. We compiled the results to assess which SNP-SNP model signals
replicated across respective cohorts. Significance of replication was assessed by correcting
the likelihood ratio test p-value for the number of original (i.e. non-proxy) models tested
and for the 10 replication cohorts. We also assessed how many of the 10 cohorts had
significant replication for each of the models. These results were visualized using the
program SynthesisView [25].Results
Discovery and replication
Full results from the discovery analysis for all original models selected for replication
testing can be found in Additional file 1: Table S1 and S2. The counts for the number
of significant models that were identified and then tested in the replication cohort can
be found in Fig. 1.
Significance in the replication cohort was estimated by using the number of original
models tested in each study design (i.e. not counting the proxy models) and the num-
ber of replication cohorts (further divide by 10) to perform a Bonferroni-like correction
equivalent to p = 0.05. For the MEF analyses, the number of original (non-proxy)
models selected for testing are shown as: lipid trait (model count, corrected p-value) -
HDL-C (156, p = 0.00003); LDL-C (160, p = 0.00003); TC (180, p = 0.00003); and TG
(187, p = 0.00003). The respective counts for the Biofilter analysis were: HDL-C (22,
p = 0.0002); LDL-C (22, p = 0.0002); TC (21, p = 0.0002); and TG (49, p = 0.0001). We
then calculated the number of model signals that passed the respective thresholds in
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then only one model signal was counted) (Fig. 1).
The models that passed the main effect filter and Biofilter replication significance
threshold are shown in Tables 1 and 2, respectively. Results are shown for models with
the same direction of effect as the discovery datasets and/or the lowest p-value, where
replication was observed in more than one cohort. For the main effect filter analyses,
more models passed the selected replication threshold. Also, a number of models showed
similar results in more than one cohort. For HDL-C, 17 total models replicated with seven
models observed to replicate in at least two cohorts. For LDL-C, two models replicated,
both in at least two cohorts. For TC, replication occurred for one model in one cohort.Table 2 Discovery and replication results for models passing replication thresholds for each lipid
trait for main effect filter analysis
Disc.
Rank
SNP 1 SNP 2 Locus 1 Locus 2 Beta LRT p Rep.
Beta
Rep. LRT p Rep.
Cohorta
HDL 1 rs12720918 rs4783961 CETP CETP −0.06 9.5 × 10−20 −0.07 3.0 × 10−12 P,W,L
2 rs12720918 rs158477 CETP CETP −0.06 6.3 × 10−16 −0.07 2.9 × 10−10 P,W,L
3 rs1864163 rs4783961 CETP CETP −0.06 4.5 × 10−15 −0.05 7.1 × 10−7 P,W,B
5 rs1864163 rs158477 CETP CETP −0.06 1.3 × 10−12 −0.05 2.3 × 10−8 P
6 rs12708967 rs820299 CETP CETP 0.06 1.0 × 10−11 0.06 1.6 × 10−6 P,W,L
7 rs1864163 rs4784744 CETP CETP 0.05 2.6 × 10−11 0.06 5.2 × 10−11 P,W
8 rs1800775 rs4783961 CETP CETP 0.04 6.3 × 10−11 −0.08 2.4 × 10−7 B
9 rs12708967 rs158477 CETP CETP −0.05 2.5 × 10−10 −0.06 1.1 × 10−6 P,W,L
10 rs9939224 rs4783961 CETP CETP −0.05 2.5 × 10−10 −0.04 2.4 × 10−7 W,B
12 rs1800775 rs158477 CETP CETP 0.04 1.8 × 10−8 0.07 2.5 × 10−6 B
13 rs9939224 rs478474 CETP CETP 0.04 5.4 × 10−7 0.07 2.4 × 10−10 P
17 rs1800775 rs4784744 CETP CETP −0.03 1.8 × 10−6 −0.05 9.7 × 10−7 W
18 rs9939224 rs12447924 CETP CETP 0.05 1.8 × 10−6 0.06 5.3 × 10−7 P
38 rs7013777 rs9644636 LPL LPL −0.03 8.0 × 10−5 −0.04 7.5 × 10−6 W
50 rs820299 rs8056954 CETP SLC12A3 0.03 1.8 × 10−4 0.06 1.5 × 10−5 W
66 rs12708967 rs4784744 CETP CETP 0.03 3.0 × 10−4 0.05 2.4 × 10−5 P
133 rs6586891 rs285 LPL LPL −0.02 7.9 × 10−4 −0.04 2.9 × 10−5 P
LDL 7 rs1531517 rs519113 BCL3 PVRL2 −0.16 7.9 × 10−6 −0.2 5.2 × 10−6 P,B
70 rs4803766 rs157580 PVRL2 TOMM40 −0.06 3.4 × 10−4 −0.11 4.8 × 10−7 P,B
TC 33 rs11216129 rs10750097 BUD13 APOA5 −0.12 1.3 × 10−4 −0.22 1.4 × 10−5 W
TG 1 rs4938303 rs180327 BUD13 BUD13 0.09 1.2 × 10−21 0.08 9.5 × 10−7 P,W
2 rs2075295 rs6589568 BUD13 APOA4 −0.10 4.4 × 10−19 −0.15 3.5 × 10−15 P,W
3 rs180327 rs10750097 BUD13 APOA5 0.08 3.1 × 10−14 0.31 6.8 × 10−9 W,B
4 rs180327 rs2075295 BUD13 BUD13 0.07 8.9 × 10−13 0.07 1.5 × 10−5 P
5 rs180327 rs6589568 BUD13 APOA4 0.07 2.7 × 10−10 0.08 5.6 × 10−6 W
6 rs11216129 rs10750097 BUD13 APOA5 −0.12 2.1 × 10−9 −0.12 2.6 × 10−7 W,P
13 rs180327 rs618923 BUD13 ZPR1 −0.08 3.7 × 10−7 −0.08 1.0 × 10−5 W
15 rs2075295 rs1263173 BUD13 APOA4 −0.08 2.1 × 10−7 −0.08 3.5 × 10−6 W
19 rs486394 rs4938303 BUD13 BUD13 0.07 2.1 × 10−6 0.07 2.9 × 10−5 P
49 rs2075295 rs10047459 BUD13 APOA1 −0.11 2.1 × 10−5 −0.11 6.9 × 10−8 W
153 rs2075295 rs10750097 BUD13 APOA5 −0.09 2.1 × 10−4 −0.09 2.9 × 10−6 W
LRT likelihood ratio test. aSee Table 1 for details on cohorts
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(Table 2). For the Biofilter analyses, results were replicated for the TG trait with two
models passing the significance threshold in a single cohort (Table 3).
Although we performed LD pruning prior to the interaction analyses, moderate LD
remained with r2 < 0.6. This resulted in residual correlation in the top replicating
models, and separate models may actually represent a single interaction signal. Addition-
ally, all of the replicating models contained two SNPs in the same gene/region. To assess
this, we looked at the pairwise r2values amongst all SNPs in the top replication models.
The goal was to identify independent replication signals and to ensure that the interaction
signals are not being inflated by LD between model SNPs. For the main effect filter ana-
lysis of HDL-C, we identified three sets of moderately correlated SNPs and two interaction
signals (Set 1 x Set 2 and Set 2 x Set 3), as shown in Fig. 2. No correlation (r2 > 0.1) was
observed in our data between SNPs in the same replication model.
For the main effect filter analyses of TG, the signals that replicated were in a similar
region on chromosome 11. This region includes several genes with strong main effects
on TG levels, including APOA4, APOA5, APOC3, SIK3, and BUD13. There are com-
plex patterns of moderate to strong LD in this region, and thus bona fide “independent”
signals are challenging to delineate. However, for the main effect filter analyses of TG,
one SNP (rs180327) appeared in two of the four models that replicated in more than
one cohort. Moderate correlation exists between most of the other SNPs except for
rs180327 (Fig. 3). This suggests a single signal representing an interaction between
rs180327 (or a correlated functional variant) and the other variants for the four models
that include this SNP. For the main effect filter analysis of LDL, two models replicated
in more than one cohort. While the SNPs from the two models are in a similar region
on chromosome 19 encompassing genes such as APOE, BCL3, PVRL2, and TOMM40,
these appear to consist of two separate interaction signals. No models replicated in
HDL-C, LDL-C, or TC for the Biofilter analyses.
To further summarize the replication analyses, we plotted the compiled results to view
all of the cohorts’ results simultaneously for each of the analyses with significant replication
(Figs. 4, 5, 6, 7 and 8). In these figures, we show the models that replicated at the
aforementioned thresholds. As some of the replications are in proxy models (not the ori-
ginal discovery model), we show the lead significant result for the each replicating model.
Discussion
For this study, we used two different filtering pipelines to test for SNP-SNP interactions
that are associated with four plasma lipid level traits: LDL-C, HDL-C, TC, and TG plasma
levels. We tested these models in a large discovery cohort and then tested the top models
in ten replication sets. Models signals passed the replication threshold for each of the lipid
traits in the main effect filter analysis and for TG in the Biofilter analysis. As expected,
replication of the observed association was found to be dependent on the size of theTable 3 Models that passed replications threshold for the TG trait for Biofilter analysis
Disc. Rank SNP 1 SNP 2 Locus 1 Locus 2 Beta LRT p Rep. Beta Rep. LRT p Rep.
Cohorta
TG 9 rs11216162 rs1263173 SIK3 APOA4 −0.05 5.5 × 10−5 −0.08 5.5 × 10−5 P
44 rs625145 rs1263173 SIK3 APOA4 −0.04 6.8 × 10−5 −0.07 6.8 × 10−5 P
No models passed replication for HDL-C, LDL-C, or TC, LRT likelihood ratio test. a See Table 1 for details on cohorts
Fig. 2 Pairwise r2 values for SNPs in top models for main effect filtering (MEF) analysis of HDL-C levels. The
numbers in the boxes are r2 values and darker shading indicates higher LD. The numbers below the SNPs
are an indicator of location in this region. Correlation patterns indicate three sets of SNPs and two interaction
signals based on replication results (Set 1 x Set 2 and Set 2 x Set 3)
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may indicate a statistical bias due to strong main effects. However, the interaction signals
appear robust, considering the number of models tested, indicating that this is unlikely
the sole driver of these significant interactions.
Genetic interactions are often described as gene-gene interactions, and are usually
studied by specifically looking for variants in different genes that could be indicating
novel pathways (e.g. protein-protein interactions that have not been previously identi-
fied using genetic data). However, intergenic interactions, such as those that we ob-
served in this study, should not be ignored, as they may contribute to a substantial
proportion of the genetic architecture. Our top replicating models for HDL-C consisted
of two SNPs in CETP. Many of these model replicated across cohorts with the top rep-
lication p-value for the likelihood ratio test being 3.0 × 10–12 (Table 2 and Additional
file 1: Table S1). LD patterns suggest that there are three independent sets of SNPs that
represent many of the top models for the CETP-HDL associations. Further, many of
these SNPs are in the promoter region of CETP. Most notably, a previous study identi-
fied a functional interaction between two of the SNPs in one of our top models (model
9: rs4783961 and rs1800775) that resulted in changes in CETP promoter activity [26].
Fig. 3 Pairwise r2 values for SNPs in top models for the main effect filtering (MEF) replication analysis of
plasma triglyceride (TG) levels. The numbers in the boxes are r2 values and darker shading indicates higher
LD. The numbers below the SNPs are an indicator of location in this region. Correlation patterns indicate a
single signal representing an interaction between rs180327 (or a correlated functional variant) and the other
variants for the four models that include this SNP
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may result in non-linear changes in CETP and HDL-C levels when the variants occur
together. These results provide further support for studying intergenic non-linear
effects and that they could be important for both accurate phenotype prediction and
for understanding the function behind why specific variants in this gene have certain
effects on HDL-C levels.
Due to the complex nature of estimating heritability, we focus on how our results
contribute to understanding the genetic architecture and biological underpinnings of
lipid traits. First, the estimated heritability of lipid traits has a relatively wide range
(40–60%). There is also high variability in results that can come from methods that cal-
culate overall heritability. A recent study found that for certain models, the estimate is
extremely inflated and potentially not reliable [12]. Furthermore, because we are study-
ing genetic interactions, reliably calculating the overall contribution to trait variation
becomes even more complicated, and many methods are not designed to accurately
generate these estimates.
In our study, we can see the difference in R2 for the full versus reduced model
(Diff|Rsq column in Additional file 1: Table S1 and S2) is usually about 0.001. Even
though this is much smaller than the R2 for the reduced model, which does not include
the interaction term, it would be inaccurate to conclude that the interaction term is
not contributing to the underlying genetic variation for a number of reasons. Firstly,
the reduced model includes the contribution of highly relevant clinical and environmental
variable (e.g. smoking status, medication, BMI, sex). Secondly, we are calculating this
Fig. 4 Results for the main effect filter (MEF) analysis of HDL-C. Showing results for the models that passed
the replication threshold of p < 3.0 × 10–5. Orig# and prox# designate models that were identified in the
discovery cohort and those identified via proxy (i.e. both SNPs in high LD with SNPs from orig. Models),
respectively. V1 and V2 are the two SNPs in the model; arrow in likelihood ratio test (LRT) row denotes
direction of effect
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plicative and that the effect of minor alleles is additive. While this model is robust to
some interactions that don’t meet these assumptions [13], the estimates themselves
could be under-estimated (or over-estimated). As we are not the first group to look
for genetic interactions amongst lipid traits, it will be very important for a future
study to be done that takes into account all of the identified main and interaction ef-
fects to assess and compare the contribution of each to trait variability. However, this
is outside the scope of our current manuscript.
Many questions remain to be answered in regards to a gold-standard genome-wide
or candidate-loci interaction analysis protocol. For example, the overwhelming majority
of our replicating interaction models were in the same gene. This is most likely due to
Fig. 5 Results for the main effect filter (MEF) analysis of LDL-C. Showing results for the models that
passed the replication threshold of p < 3.0 × 10–5. Orig# and prox# designate models that were identified in
the discovery cohort and those identified via proxy (i.e. both SNPs in high LD with SNPs from orig. Models),
respectively. V1 and V2 are the two SNPs in the model; arrow in likelihood ratio test (LRT) row denotes
direction of effect
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Fig. 6 Results for the main effect filter (MEF) analysis of TC. Showing results for the models that passed
the replication threshold of p < 3.0 × 10–5. Orig# and prox# designate models that were identified in the
discovery cohort and those identified via proxy (i.e. both SNPs in high LD with SNPs from orig. Models),
respectively. V1 and V2 are the two SNPs in the model; arrow in likelihood ratio test (LRT) row denotes
direction of effect
Holzinger et al. BioData Mining  (2017) 10:25 Page 14 of 20
Fig. 7 Results for the main effect filter (MEF) analysis of TG. Showing results for the models that passed
the replication threshold of p < 3.0 × 10–5. Orig# and prox# designate models that were identified in the
discovery cohort and those identified via proxy (i.e. both SNPs in high LD with SNPs from orig. Models),
respectively. V1 and V2 are the two SNPs in the model; arrow in likelihood ratio test (LRT) row denotes
direction of effect
Holzinger et al. BioData Mining  (2017) 10:25 Page 15 of 20
Fig. 8 Results for the Biofilter analysis of TG. Showing results for the models that passed the replication
threshold of p < 3.0 × 10–5. Orig# and prox# designate models that were identified in the discovery cohort
and those identified via proxy (i.e. both SNPs in high LD with SNPs from orig. Models), respectively. V1 and
V2 are the two SNPs in the model; arrow in likelihood ratio test (LRT) row denotes direction of effect
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Holzinger et al. BioData Mining  (2017) 10:25 Page 17 of 20the fact that our variants were genotyped using a gene-centric chip with genes that are
known to have effects on cardiovascular-related phenotypes, like the lipid levels we an-
alyzed in this study. A chip that had more extensive coverage outside of these genes
may have identified more interactions between functionally different parts of the gen-
ome. However, our focused analysis did allow us to efficiently test two unique filtering
pipelines for a more hypothesis-driven approach. These filtering approaches each have
their own strengths and weaknesses. The Biofilter 2.0 analysis, which created gene-gene
models based on current biological knowledge, allows for clearer interpretations as the
models make biological sense. However, it inhibits the discovery of interactions in
regions where biological knowledge is limited. The main effect filter analysis is more
robust to discovering interactions that deviate from regions of current biological focus
than the Biofilter pipeline in this particular dataset. However, if the main effects of the
true interaction model are non-existent (i.e. purely epistatic models where each of the
SNPs in the interaction model are not significant alone), the main effect filter pipeline
would not detect such effects. Also, as our results possibly indicate, strong main effects
may create inflated interaction signals. A more appropriate filtering pipeline may use a
main effect filter – Biofilter hybrid approach. Another possible filtering mechanism
may be one that ranks variables based on potential main and interaction effects simul-
taneously. Some machine learning methods, such as Random Forests (RF) and artificial
neural networks (ANN), are currently being tested for this approach [27].
Additional file
Additional file 1: Table S1. Discovery results for all models that passed replication thresholds for MEF analysis.
Column header definitions provided at the end. Table S2. Discovery results for all models that passed replication
thresholds for Biofilter analysis. Column header definitions provided at the end. (PDF 1649 kb)
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